Health Care & Life Sciences » Pharmaceuticals | Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang Pharmaceutical Corp. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
16,277
55,304
16,677
21,721
45,471
45,949
Total Accounts Receivable
160,615
161,656
175,932
209,634
210,298
208,288
Inventories
71,155
75,236
89,983
98,261
104,339
127,591
Other Current Assets
7,255
6,238
5,773
9,142
6,796
8,503
Total Current Assets
255,303
298,435
288,365
338,757
366,904
390,331
Net Property, Plant & Equipment
214,686
215,240
228,027
244,676
252,377
254,109
Total Investments and Advances
31,361
44,005
44,051
40,636
38,990
46,213
Intangible Assets
17,834
16,074
15,844
14,858
14,334
15,376
Other Assets
2,767
-
-
2,771
4,600
3,267
Total Assets
521,951
573,754
576,287
641,699
677,205
711,495
ST Debt & Current Portion LT Debt
63,567
80,600
53,967
84,567
81,100
Accounts Payable
34,407
40,051
49,529
71,204
71,181
Income Tax Payable
165
4,960
7,361
13,866
15,287
Other Current Liabilities
32,713
35,707
40,586
41,805
56,480
Total Current Liabilities
130,853
161,317
151,443
211,442
224,048
Long-Term Debt
61,000
43,967
70,600
40,000
21,358
Provision for Risks & Charges
15,343
21,120
27,013
27,329
18,391
Deferred Taxes
6,954
5,886
2,968
997
2,277
Other Liabilities
9,677
10,017
9,702
7,680
7,836
Total Liabilities
223,827
242,306
261,726
287,448
273,910
Common Equity (Total)
298,124
331,448
314,561
354,250
401,715
Total Shareholders' Equity
298,124
331,448
314,561
354,250
401,715
Total Equity
298,124
331,448
314,561
354,250
403,295
Liabilities & Shareholders' Equity
521,951
573,754
576,287
641,699
677,205
Accumulated Minority Interest
-
-
-
-
1,580

About Chong Kun Dang Pharmaceutical

View Profile
Address
8 Chungjeong-ro
Seoul SL 03742
Korea, Republic Of
Employees -
Website http://www.ckdpharm.com
Updated 07/08/2019
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 2, 2013 and is headquartered in Seoul, South Korea.